Illumina completed acquisition of SomaLogic and related Sengenics assets in a cash transaction, securing proteomics capabilities and a CLIA/CAP lab in Boulder, Colorado. The deal brings SomaLogic’s SomaScan aptamer platform into Illumina’s sequencing and multiomics ecosystem and includes up to $75 million in near‑term milestones and a royalty arrangement. Illumina plans to integrate SomaLogic’s protein measurement technology with its NGS portfolio and DRAGEN analytics to accelerate proteomics‑driven discovery and translational applications. The company stated there are no immediate operational changes in Boulder and that it will leverage global operations to expand access. The transaction positions Illumina to offer end‑to‑end multiomics solutions for biomarker discovery and clinical research, potentially reshaping protein assay scale and cost for translational programs.